Serum metabolomic analysis in cirrhotic alcohol-associated liver disease patients identified differentially altered microbial metabolites and novel potential biomarkers for disease severity
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.10.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Nathan Calzadilla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Illinois Chicago, Chicago, IL, United States. Hauptthemen laut MEDLINE: Biomarkers, Metabolomics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, BLRD VA, NIDDK NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Alcohol-Associated Liver Disease (ALD) is a leading cause of liver mortality. Mechanisms responsible for severe ALD and the roles of gut microbiota are not fully understood. Multi-omics tools have enabled a better understanding of metabolic alterations and can aid in identifying metabolites as biomarkers for severe ALD. AIMS: Examine differences between cirrhotic and non-cirrhotic ALD, investigate microbial contributions to such changes, and identify potential diagnostic and prognostic metabolites for severe ALD. METHODS: Untargeted metabolomics were performed on the serum of 11 non-cirrhotic and 11 cirrhotic ALD patients. Data were analyzed using MetOrigin and Metaboanalyst to identify enriched pathways. RESULTS: Increased methylated nucleotides, gamma-glutamyl amino acids, bile acids, and specific metabolites kynurenine and campesterol were increased in ALD cirrhosis, whereas branched-chain amino acids, serotonin, and xanthurenate were decreased. Microbial contributions included increases in the short-chain fatty acid indolebutyrate and methionine sulfoxide in ALD cirrhosis. The analysis also identified the potential for serum levels of 3-ureidopropionate, cis-3,3-methyleneheptanoylglycine, retinol, and valine to be used as biomarkers for clinical assessment of alcohol-associated cirrhosis. CONCLUSION: We have identified a set of metabolites that are differentially altered in cirrhotic compared to non-cirrhotic ALD that can potentially be used as biomarkers for the severity of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Illinois Chicago, Chicago, IL, United States.
- Division of Gastroenterology & Hepatology, Rush University, Chicago, IL, United States.
- Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, United States.
- Division of Gastroenterology & Hepatology, University of Illinois Chicago, Chicago, IL, United States.
- Division of Gastroenterology & Hepatology, University of Illinois Chicago, Chicago, IL, United States; Jesse Brown VA Medical Center, Chicago, IL, United States. Electronic address: walrefai@uic.edu.
Förderung
- NIAAA NIH HHS
- BLRD VA
- NIDDK NIH HHS
Zitieren
APA
Calzadilla, N., Zilberstein, N., Hanscom, M., Al Rashdan, H. T., Chacra, W., Gill, R. K., & Alrefai, W. A. (2024). Serum metabolomic analysis in cirrhotic alcohol-associated liver disease patients identified differentially altered microbial metabolites and novel potential biomarkers for disease severity. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.10.006
Vancouver
Calzadilla N, Zilberstein N, Hanscom M, Al Rashdan HT, Chacra W, Gill RK, et al. Serum metabolomic analysis in cirrhotic alcohol-associated liver disease patients identified differentially altered microbial metabolites and novel potential biomarkers for disease severity. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.10.006
BibTeX
@article{Calzadilla2024,
author = {Calzadilla, Nathan and Zilberstein, Netanel and Hanscom, Mark and Al Rashdan, Haya T and Chacra, Wadih and Gill, Ravinder K and Alrefai, Waddah A},
title = {Serum metabolomic analysis in cirrhotic alcohol-associated liver disease patients identified differentially altered microbial metabolites and novel potential biomarkers for disease severity},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.10.006}
}
EUVIMED